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Serum osteoprotegerin is 
associated with pulse pressure in 
kidney transplant recipients
Zsofia K. Nemeth1,*, Nicoleta G. Mardare2,*, Maria E. Czira3, Gyorgy Deak1, Istvan Kiss4,5,6, 
Zoltan Mathe7, Adam Remport7, Akos Ujszaszi8, Adrian Covic9, Miklos Z. Molnar10 & 
Istvan Mucsi11
Pulse pressure (PP) reflects increased large artery stiffness, which is caused, in part, by arterial 
calcification in patients with chronic kidney disease. PP has been shown to predict both 
cardiovascular and cerebrovascular events in various patient populations, including kidney transplant 
(KTX) recipients. Osteoprotegerin (OPG) is a marker and regulator of arterial calcification, and it is 
related to cardiovascular survival in hemodialysis patients. Here we tested the hypothesis that OPG 
is associated with increased pulse pressure. We cross-sectionally analyzed the association between 
serum OPG and PP in a prevalent cohort of 969 KTX patients (mean age: 51 +/− 13 years, 57% male, 
21% diabetics, mean eGFR 51 +/− 20 ml/min/1.73 m2). Independent associations were tested in a 
linear regression model adjusted for multiple covariables. PP was positively correlated with serum 
OPG (rho = 0.284, p < 0.001). Additionally, a positive correlation was seen between PP versus age 
(r = 0.358, p < 0.001), the Charlson Comorbidity Index (r = 0.232, p < 0.001), serum glucose (r = 0.172, 
p < 0.001), BMI (r = 0.133, p = 0.001) and serum cholesterol (r = 0.094, p = 0.003). PP was negatively 
correlated with serum Ca, albumin and eGFR. The association between PP and OPG remained 
significant after adjusting for multiple potentially relevant covariables (beta = 0.143, p < 0.001). 
We conclude that serum OPG is independently associated with pulse pressure in kidney transplant 
recipients.
Cardiovascular (CV) disease is the leading cause of death in kidney transplant (KTX) recipients1,2. 
Factors related to mineral and bone disorders (MBD) are important novel cardiovascular risk factors 
among patients with chronic kidney disease (CKD)3–5. MBD is thought to contribute to accelerated vas-
cular calcification in these patients6,7. Although disorders of bone and mineral metabolism improve after 
KTX, they remain frequent in kidney transplant recipients8 and may contribute to increased CV risk.
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Accelerated age-related arterial remodeling and also vascular calcification lead to the loss of large and 
small vessel distensibility in patients with CKD and end stage kidney disease (ESKD). These changes 
manifest in increased vascular stiffness, frequently assessed by pulse wave velocity (PWV)9. Increased 
vascular stiffness contributes to profound changes in circulatory function, including an increase in sys-
tolic blood pressure (SBP) and widening of pulse pressure (PP)10. Pulse pressure (PP), easily available 
from blood pressure (BP) determination in everyday clinical practice, is considered a surrogate for arte-
rial stiffness11. PP independently predicted the risk of death in a large cohort of hemodialysis (HD) 
patients12.
Most13,14 but not all15 studies reported that KTX improves vascular stiffness. Impaired graft function16 
or new onset diabetes17, however, were associated with increased stiffness in this patient population. 
Vascular stiffness and calcification has been repeatedly shown to predict poor clinical outcome after 
KTX18,19. Increased PP is also an independent predictor of cardiovascular events and premature car-
diovascular mortality in KTX recipients20. The link between PP and clinical outcome is likely due to, 
at least in part, vascular stiffness, similarly to the link between PP and kidney function21. Importantly 
PP is associated with mineral metabolism abnormalities10 suggesting a link between MBD and vascular 
stiffness and CV disease.
Studies have indicated a role for osteoprotegerin (OPG), a soluble decoy receptor of the osteoclast 
activator RANKL, in arterial calcification and atherosclerosis22-24. Elevated OPG levels were associated 
with faster progression of vascular calcifications25, with PWV and mortality in patients on maintenance 
dialysis26-28 and with CKD29,30.
Studies in kidney transplant recipients revealed that serum OPG declined during the first 2 weeks 
after KTX and decreased further during the next 2 weeks31. Nonetheless, post-transplant OPG levels 
predicted coronary32 and aortic33 calcifications and also mortality34,35 in KTX patients.
In this cross-sectional prevalent cohort study we tested the hypothesis that elevated serum OPG is 
associated with increased PP, an easily available surrogate of arterial stiffness and vascular calcification, 
independent of potential confounding variables in kidney transplant recipients.
Methods
Patient population and data collection.  All prevalent kidney transplant recipients 18 years of age 
or older (n = 1214) followed at a single transplant clinic at Semmelweis University in Budapest, Hungary 
were invited to participate in this observational cohort study. Exclusion criteria were acute rejection 
within the last 4 weeks, current hospitalization, transplantation in the previous 3 months, acute infection 
or active bleeding. Of the 993 subjects enrolled, 982 (99%) had baseline blood samples that were available 
for osteoprotegerin (OPG) assay. All subjects were recruited and baseline assessments were conducted 
between February 2007 and August 2007 (Malnutrition-Inflammation in Transplant-Hungary Study; 
MINIT-HU Study). The study methods have been previously described36.
Ethical  approval.  The study was approved by the Ethics Committee of the Semmelweis University 
(49/2006). Before enrolment, patients received detailed verbal and written information about the aims 
and protocol of the study and signed informed consent. All experiments were performed in accordance 
with relevant guidelines and regulations.
Laboratory  data.  Routinely available laboratory data were extracted from the patients’ charts and 
from the hospital’s electronic laboratory database. Estimated glomerular filtration rate (eGFR) was cal-
culated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation37. The fol-
lowing laboratory parameters were tabulated: hemoglobin (Hb), serum C-reactive protein (CRP), total 
cholesterol, HDL- and LDL-cholesterol, triglyceride, calcium, phosphorus, total alkaline phosphatase, 
albumin, creatinine and blood urea nitrogen (BUN). Serum intact parathyroid hormone (PTH) (pg/ml) 
was determined by second-generation electrochemiluminescence assay (iPTH Elecsys System; Roche, 
Mannheim, Germany).
Serum samples were also collected at the time of the baseline assessment and stored at − 70 °C for 
future use. Serum osteoprotegerin was measured with an immunoassay kits based on a solid-phase sand-
wich enzyme-linked immunosorbent assay (ELISA) (Biomedica, Vienna, Austria).
Co-morbidities and blood pressure measurement.  We used the modified Charlson Comorbidity 
Index (CCI)38, which is a weighted scoring system based on the presence or absence of each of 17 
variables. Earlier it has been reported that the CCI was a predictor of survival in kidney transplanted 
patients39. Each patient enrolled in this study underwent a physical examination and subjective global 
assessments (SGA) (in order to determine the Malnutrition-Inflammation Score) by a physician (ME 
Czira) at the baseline visit. Blood pressure was recorded as part of this exam. One calibrated mercury 
sphygmomanometer was used for each participant. Blood pressure was recorded as the average of three 
readings after ten minutes rest during the baseline clinic visit.
Immunosuppressive therapy.  Standard maintenance immunosuppressive therapy at our institution 
consisted of prednisolone, either cyclosporine A microemulsion formulation (CsA) or tacrolimus, com-
bined with mycophenolate-mofetil (MMF) or azathioprine or sirolimus.
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Statistical analysis.  We used descriptive statistics to compare clinical and biochemical characteris-
tics across tertiles of baseline serum OPG. Data were summarized using proportions, means (±standard 
deviation, SD) or medians (interquartile range, IQR) as appropriate. Normality of the distribution of 
continuous variables was checked with the Kolmogorov-Smirnov test. Variables with skewed distribution 
were natural log-transformed for all analyses. Correlation between serum OPG and PP versus continuous 
variables was tested with Pearson correlation analysis. To compare variables between tertiles of serum 
OPG, one-way analysis of variance (ANOVA) or the Chi-square test was used.
All variables which correlated with PP with a level of significance < 0.01 in these analyses (given 
the relatively large sample size and multiple analyses) were included in a multivariable linear regression 
model. Because of the relatively large number of the variables entered in the final model, variables were 
entered in five blocks. First serum OPG alone was added; block B included age, sex, presence of diabe-
tes, body mass index (BMI), the Charlson comorbidity index and cumulative end stage kidney disease 
(ESKD) vintage; the next block included the use of immunosuppressive medications: steroids, cyclo-
sporine, tacrolimus, azathioprine, mycophenolate-mofetil and sirolimus; block D included eGFR, serum 
albumin, glucose and cholesterol, the final block included serum calcium, phosphorus, PTH, the use of 
active vitamin D and the use of phosphate (PO4) binders. All variables were retained in the final model. 
Non-linear association between OPG versus PP was tested using the squared OPG term in the regression 
model and restricted cubic spline. Variance influence factors (VIF) were used to indicate collinearity 
between independent variables in the multivariate regression model. For all analysis, two-sided p values 
are reported and results have been considered statistically significant if p < 0.05.
Data were analyzed using the IBM SSPS Statistics for Macintosh 22.0 software (IBM® Corp. Armonk, 
NY) and STATA MP version 13.1 (STATA Corp., College Station, TX).
Results
Baseline characteristics of the sample are shown in Table  1. Mean age of the participants was 51 ± 13 
years, 57% were male, 21% diabetic and 94% had hypertension. Median transplant vintage was 77 months 
(IQR: 41–121). Most of the patients were on steroids, mycophenolate mofetil and calcineurin inhibitors 
for immune suppression (see Table  1). The etiology of the underlying kidney disease was chronic glo-
merulonephritis in 23%, autosomal polycystic kidney disease in 18%, tubulointerstitial nephropathies in 
13%, diabetic nephropathy in 5%, hypertensive nephropathy in 7%, other or unknown renal disease in 
34% of patients. Antihypertensive medication administered included beta blockers in 717 (74%) patients, 
ACE inhibitors or angiotensin receptor blockers (ARB) in 288 (30%), calcium channel blockers in 537 
(55%) individuals and diuretics in 323 (33%).
Associations between serum OPG tertiles versus several clinical and laboratory variables are also 
demonstrated in Table 1. Importantly, PP increased significantly with higher OPG tertiles (p < 0.001 for 
trend) and PP was significantly correlated with serum OPG levels (R = 0.284; p < 0.001) (Table  2 and 
Fig. 1). This association was significant in both younger and older individuals (below and above the mean 
age of the sample), among participants with preserved and more impaired eGFR (above and below of the 
mean eGFR of the sample), in patients with higher and more controlled blood pressure (above and below 
the mean systolic BP), among males and females and also in diabetics and non-diabetics (not shown).
Patients in the higher OPG tertiles were significantly older, were less likely male but more likely 
diabetic, and had somewhat lower BMI. The utilization of several immunosuppressive medications was 
also associated with OPG tertiles (Table 1). Patients in higher OPG tertiles had longer ESRD duration 
and lower eGFR, lower hemoglobin and serum albumin but higher phosphorus, PTH and alkaline phos-
phatase concentrations and higher Ca x P product. Finally, higher OPG tertiles were asociated with more 
comorbidities (Table  1). The association between serum OPG versus the mentioned variables was also 
demonstrated in correlation analysis (Table 2).
We also analyzed correlations between PP and demographic and clinical variables. PP was higher 
in males versus females (59 ± 16 vs 56 ± 17, p = 0.006) among patients with diabetes vs non-diabetics 
(65 ± 19 vs 56 ± 16, p < 0.001). PP was also significantly correlated with age, body mass index, hemo-
globin level, total serum cholesterol, eGFR, serum albumin and serum glucose levels and the Charlson 
Comorbidity Index (Table 2).
To test if the association between OPG versus PP is independent of the potentially confounding 
covariables we built a multivariable linear regression model with PP as the dependent variable. As 
described in the Methods section, independent variables were entered in five blocks. Importantly, 
OPG was independently associated with PP in the fully adjusted final model (R2 = 0.233, beta = 0.143; 
p < 0.001) (Table 3). Additional independent predictors of PP in this model were age, sex, the Charlson 
Comorbidity Index, the presence of diabetes, use of cyclosporine A, and serum calcium (Table 4).
Discussion
Here we demonstrated for the first time, in a large prevalent cohort of KTX patients that serum OPG 
levels were independently associated with pulse pressure, a surrogate marker of arterial stiffness and a 
cardiovascular risk factor. These results are compatible with the potential contribution of osteoprotegerin 
and also of CKD-MBD to increased CV risk in KTX recipients.
PP increases with declining eGFR in patients with CKD. It is also associated with age, the presence 
of diabetes mellitus and hypertension, serum phosphorus and PTH levels in this patient population40. 
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Furthermore, PP appears to be significantly associated with age, sex, diabetes and dialysis vintage in 
hemodialysis patients after adjustment for systolic blood pressure12. Fernandez-Fresnedo et al. found that 
higher PP was associated with recipient age, systolic and diastolic blood pressure, presence of diabetes 
and cardiovascular disease in KTX recipients41. In our study PP was significantly associated with age 
and the presence of diabetes, consistent with previously published literature. Besides these factors, PP 
was also associated with cumulative ESRD time and eGFR, suggesting that kidney transplantation can 
not restore vascular lesions caused by prolonged uremia. Furthermore, progressive decline of the renal 
function due to chronic allograft injury could also play a role in determining arterial changes in these 
patients.
Elevated pulse pressure is a marker of arterial stiffness and is clearly associated with adverse cardio-
vascular outcomes42,43. In patients with CKD vascular calcification is thought to importantly contribute 
to vascular stiffness. Although the exact molecular mechanism of accelerated vascular calcification seen 
in patients with CKD is not fully understood, it has been repeatedly demonstrated that regulators of bone 
a mineral metabolism play a role in this pathophysiological process7,44,45. One of those factors is osteopro-
tegerin, a known inhibitor of osteoclastogenesis and bone resorption46. Interestingly, several animal mod-
els suggested a protective role for OPG against vascular calcification. Selective deletion of OPG in mice 
results in early-onset severe osteoporosis as well as significant medial calcification of the aorta and renal 
arteries47. In animal models OPG seems to prevent vascular calcification but is unable to reverse lesions 
once calcification has occurred48,49. Contrary to the apparent protective role of OPG observed in the ani-
mal models, higher serum levels of OPG are reportedly associated with increased vascular calcifications 
Total sample 
(n = 969)
Tertiles of serum OPG (pmol/L)
p for 
trend1st (<3.20) 2nd (3.20–4.39)
3rd 
(>4.39)
Pulse pressure (mmHg) 58 ± 17 53 ± 14 57 ± 17 63 ± 18 < 0.001
Age (years) 51 ± 13 44 ± 13 51 ± 12 57 ± 10 < 0.001
Sex (male) 559 (57) 198 (63) 191 (58) 173 (52) 0.02
Charlson Comorbidity Index 2 (2) 2 (1) 2 (2) 3 (2) < 0.001
Diabetes mellitus (yes) 206 (21) 39 (12) 78 (24) 89 (27) < 0.001
BMI (kg/m2) 26.9 ± 4.8 27.4 ± 5 27.1 ± 4.8 26.5 ± 4.7 0.015
Tx vintage (months) 72 (75) 64.5 (82) 76 (74) 76 (71) 0.022
ESKD vintage (months) 107.5 (87) 100 (90) 108 (89) 113 (93) 0.003
Systolic BP (mmHg) 142 ± 19 138 ± 18 141 ± 19 147 ± 20 < 0.001
Diastolic BP (mmHg) 84 ± 12 85 ± 12 83 ± 12 83 ± 12 0.073
Steroids (yes) 787 (81) 255 (78) 266 (81) 277 (85) 0.070
CSA (yes) 469 (48) 145 (44) 160 (49) 172 (53) 0.088
Tacrolimus (yes) 418 (43) 164 (50) 136 (42) 122 (37) 0.003
MMF (yes) 755 (78) 269 (82) 257 (79) 240 (73) 0.029
Sirolimus (yes) 78 (8) 16 (5) 23 (7) 39 (12) 0.003
CKD-EPI eGFR (ml/
min/1.73 m2) 53 ± 22 60 ± 21 54 ± 20 44 ± 22 < 0.001
Albumin (g/l) 40 ± 4 41 ± 4 40 ± 4 39 ± 4 < 0.001
Blood glucose (mmol/l) 6.6 ± 2.6 6.3 ± 2.4 6.8 ± 2.8 6.6 ± 2.4 0.037
CRP (mg/l) 3.1 (5.3) 2.9 (4.7) 3.4 (5.4) 3.2 (5.7) 0.25
Cholesterol (mmol/l) 5.51 ± 1.27 5.36 ± 1.14 5.63 ± 1.32 5.54 ± 1.34 0.069
Trigliceride (mmol/l) 2.08 (1.29) 1.71 (1.42) 1.69 (1.31) 1.68 (1.19) 0.917
Phosphorus (mmol/l) 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.2 1.2 ± 0.3 0.001
Ca (mmol/l) 2.3 ± 0.2 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1 0.427
Ca*P (mmol2/l2) 2.5 ± 0.6 2.4 ± 0.7 2.4 ± 0.5 2.6 ± 0.6 < 0.001
PTH (pg/ml) 67 (56) 62 (47) 69 (54) 75 (75) < 0.001
Alkaline phosphatase(UI/l) 88 ± 40 85 ± 31 86 ± 34 94 ± 50 0.005
Osteoprotegerin(pmol/l) 3.9 ± 1.5 2.4 ± 0.53 3.7 ± 0.35 5.6 ± 0.11 < 0.001
Table 1. Demographic and biochemical data for all participants and for tertiles of serum OPG (data 
are presented as mean ± standard deviation (SD), median with interquartile range (IQR) or n[%] as 
appropriate).
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both in the general population and among patients with varying degree of CKD22,23,25–27,30. The reason for 
this paradoxical phenomenon is not fully explained. One potential hypothesis suggests that the elevated 
OPG levels may reflect a potential compensatory or protective reaction against procalcification factors50. 
It is also possible that OPG is a biomarker of the active calcification process in the vasculature. OPG, 
which is normally secreted by osteoblasts, may also be secreted by the osteoblast-like cells formed by 
the trans-differentiation of vascular smooth muscle cells. These cells express bone-specific proteins and 
actively deposit bone matrix in the vascular wall51.
Regardless of the yet unclear mechanistic role of OPG in vascular calcification, the clinical relevance 
of OPG lies in its prognostic potential. Serum OPG consistently predicted the presence and severity of 
coronary artery disease or mortality6,26,27,29,34,52,53. OPG levels decrease soon after kidney transplanta-
tion31 but post-transplant OPG levels are still associated with mortality in KTX patients34,35. Our results, 
demonstrating a consistent and independent association between serum OPG and pulse pressure, a 
PP (mmHg)
Osteoprotegerin 
(pmol/l)
Osteoprotegerin (pmol/l)
R = 0.284 NA
p < 0.001
Pulse pressure (mmHg)
NA R = 0.284
p < 0.001
Age (years)
R = 0.385 R = 0.419
p < 0.001 p < 0.001
Charlson Comorbidity Index
R = 0.232 R = 0.250
p < 0.001 p < 0.001
BMI (kg/m2)
R = 0.133 R = − 0.079
p < 0. 001 p = 0.014
Tx vintage (months)
R = − 0.006 R = 0.087
p = 0.845 p = 0.006
Cumulative ESKD vintage 
(months)
R = − 0.023 R = 0.107
p = 0.482 p = 0.001
eGFR
R = − 0.105 R = − 0.290
P < 0.001 P < 0.001
Hemoglobin (g/l)
R = − 0.095 R = − 0.160
p = 0.003 p < 0.001
CRP (mg/l)
R = 0.072 R = 0.023
p = 0.025 p = 0.465
se Albumin (g/l)
R = − 0.134 R = − 0.230
p < 0.001 p < 0.001
se Cholesterol (mmol/l)
R = 0.094 R = 0.041
p = 0.003 p = 0.199
se Glucose (mmol/l)
R = 0.172 R = 0.037
p < 0.001 p = 0.244
se Calcium (corrected for 
albumin) (mmol/l)
R = − 0.122 R = − 0.104
p < 0.001 p = 0.001
se Phosphorus (mmol/l)
R = 0.031 R = 0.144
p = 0.328 p < 0.001
Ca x P (mmol2/l2)
R = − 0.022 R = 0.145
p = 498 p < 0.001
Se ALP (U/l)
R = 0.002 R = 0.107
p = 0.948 p = 0.001
Se PTH (pg/ml)
R = 0.016 R = 0.075
p = 0.616 p = 0.019
Table 2. Correlation between PP and OPG versus clinical and laboratory variables.
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Figure 1. Non-linear association between OPG versus PP using restricted cubic spline. The model was 
adjusted according to model E in Table 3.
serum OPG
beta P Value R square
model A 0.284 < 0.001 0.081
model B 0.152 < 0.001 0.209
model C 0.152 < 0.001 0.216
model D 0.141 < 0.001 0.224
model E 0.143 < 0.001 0.233
Table 3. Multivariable linear regression model of pulse pressure as dependent variable to assess the 
independent association with serum OPG. Shown in the cells are the parameters of the independent 
variable serum OPG. Independent variables entered into the model: Block A: serum OPG alone; Block 
B: Block A + age, sex, presence of diabetes, BMI, the Charlson Comorbidity Index and cumulative ESKD 
vintage; Block C: Block B + use of immunosuppressive medications (steroids, cyclosporine, tacrolimus, 
azathioprine, mycophenolate-mofetil and sirolimus); Block D: Block C + eGFR, serum albumin, glucose and 
cholesterine; Block E: Block D + calcium, phosphorus, PTH, use of active vitamin D, use of PO4 binders. 
Abbreviations: OPG – Osteoprotegerin.
B
Standardized 
Coefficients
p value
95% Confidence 
Interval for B
Beta
Lower 
Bound
Upper 
Bound
Se OPG 1.636 0.143 < 0.001 0.865 2.407
Age 0.342 0.259 < 0.001 0.251 0.434
Gender − 3.968 − 0.116 < 0.001 − 6.006 − 1.930
Presence of diabetes 2.874 0.070 0.044 0.080 5.668
Charlson Comorbidity Index 0.913 0.093 0.005 0.271 1.555
Cumulative ESKD vintage − 0.016 − 0.062 0.053 − 0.033 0.000
Taking Cyclosporin A 3.749 0.111 0.047 0.047 7.451
Se Ca − 10.361 − 0.094 0.004 − 17.400 − 3.321
Table 4. Multivariable regression analysis for PP (R2 = 0.233, p < 0.001). Shown in the table are 
variables which were independently associated with PP. The final model was also adjusted for the 
following variables: BMI, use of steroids, tacrolimus, azathioprine, sirolimus and mycophenolate-mofetil, 
eGFR, se Albumin, phosphorus, glucose and PTH.
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surrogate of vascular stiffness, are consistent with the hypothesis that higher OPG level is a marker 
of vascular calcification and arterial stiffness. This is further corroborated by our finding of significant 
correlations between OPG versus markers of mineral metabolism (serum Ca, phosphorus and PTH) in 
our KTX sample, similarly to patients with CKD29 and on dialysis25.
In this study we wanted to assess the association between PP and OPG. We considered PP primarily 
as a surrogate of vascular stiffness. However, there is a complex relationship between PP and systolic and 
diastolic BP (SBP and DBP, respectively) and their predictive association with cardiovascular outcomes. 
Initially it had been thought that DBP was the most damaging component of BP. Subsequent epidemio-
logic studies, however, called attention to the relevance of SBP over DBP in inducing cardiovascular and 
renal damage54. It is well established that DBP decreases after about 50–55 years of age in the general 
population, whereas SBP progressively increases up to at least 80 years of age55. These relationships, 
however, may be different in patients with CKD, in whom atherosclerosis and arterial calcification is 
accelerated and systolic hypertension is very prevalent. Recently it has been shown that OPG levels 
correlated with systolic BP56,57. The underlying mechanism for that association was not quite clear but it 
was suggested that it may be related to vascular calcification, atherosclerosis or altered bone metabolism. 
In our dataset OPG was significantly correlated with both systolic and diastolic BP, in addition to PP. 
Furthermore, when we normalized PP to systolic BP, as recently suggested, the significant associations 
remained. The association between OPG and PP, therefore, likely reflect the underlying link between 
OPG and vascular calcification – although we cannot conclude to the directionality of this association 
from our data.
Several limitations of our study should be considered when interpreting our results. Patients from a 
single center were enrolled; therefore our results are not to be generalized without further considerations. 
Patients who were not participating in the study may have been different from participants, which is a 
potential source of bias. We think, however, that it is unlikely that this would have qualitatively changed 
our results. Only Caucasian patients participated which may make comparisons with multiethnic pop-
ulations difficult. Moreover, our patients form a heterogenic group selected at various moments in their 
evolution after renal transplantation and with various degree of kidney dysfunction so that OPG levels 
varies. Finally, we did not measure vascular stiffness in this research that would have provided additional 
new information about vascular characteristics.
In conclusion we have demonstrated that OPG is independently associated with pulse pressure in 
renal transplant patients. These results support the potential role of disordered bone and mineral metab-
olism in vascular calcifications and stiffness in kidney transplant recipients. Prospective studies will be 
necessary to demonstrate the pathophysiologic link between disordered bone and mineral metabolism 
and vascular calcification in KTX patients. Those studies will need to be informed by basic research gen-
erating new knowledge using cell culture experiments and animal models. They will need to demonstrate 
a prospective association between changing bone metabolism and increasing vascular stiffness/calcifica-
tion by utilizing multiple biomarkers of bone metabolism. This may be complemented by dual-photon 
x-ray absorptiometry or quantitative CT assessment of bone mineral density and structure. Vascular cal-
cification will need to be determined by appropriate imaging, preferably CT scanning of coronaries and/
or the aorta. This needs to be complemented by validated measurement of vascular stiffness. In addition 
to these studies, potential intervention trials that aim at modulating bone turnover, may demonstrate the 
effect (or the lack thereof) on vascular calcification of interventions that modify bone turnover.
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